June 15, 2020
Vyripharm Biopharmaceuticals, Regis Technologies in COVID-19 related deal
Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19.